<DOC>
	<DOCNO>NCT01121731</DOCNO>
	<brief_summary>The general aim study determine 3 MIU IFN-α5 monotherapy , 1,5 MIU IFN-α5 combine 1,5 MIU IFN- α2b , safe dose level well investigate antiviral efficacy pharmacodynamics ( PD ) dose drug treatment-experienced HCV patient genotype 1 chronic infection , 29 day treatment . It also intend determine pharmacokinetics ( PK ) safe dose achieve IFN-α5 monotherapy .</brief_summary>
	<brief_title>A Phase I/II Clinical Trial With Interferon Alfa 5 Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients age ≥18 year old , 2 . With chronic hepatitis C ( CHC ) infection diagnose seropositivity antiHCV antibody detectable HCVRNA , least 6 month prior screen . 3 . Patients CHC infection genotype 1 ( 1a , 1b mixed 1a/1b ) 4 . Defined relapsers : CHC patient achieve virologic response ( HCVRNA non detectable ) time standard care treatment CHC IFNα2 PegIFNα2 + ribavirin , maintain trough end treatment week 48 week , HCVRNA detection occur 6 month posttreatment . 5 . In liver cirrhosis rule fibroscan liver biopsy within 24 month prior study enrolment . 6 . With serum HCV viral load ≥ 100.000 IU/mL screen 7 . With alanineaminotransferase ( ALT ) aspartateaminotransferase ( AST ) serum measurement screen less 5 time upper limit normal ( ULN ) 8 . With body mass index ( BMI ) least 18 kg/m2 , exceed 36 kg/m2 . 9 . For female subject childbearing potential : use know highly effective method birth control 10 . For male subject partner child bear potential : use appropriate contraceptive method . 11 . Is able effectively communicate investigator test center personnel . 12 . Is able participate willing give write informed consent comply study restriction . Exclusion Criteria ( principal ) : 1 . Hepatitis C infection genotype 2 , 3 4 mixed genotype ( 1/2 , 1/3 1/4 ) . 2 . A positive ELISA HIV1 HIV2 . 3 . Hepatitis B virus ( HBV ) infection base presence HBsAg . 4 . Hepatitis A virus ( HAV ) infection base presence antiHAVIgM . ( AM 4 ) Criteria delete 5 . Decompensated liver disease , history decompensated liver disease . 6 . History evidence medical condition associate decompensated renal , immunologically mediate , chronic pulmonary , cardiac , thyroid , severe retinopathy , severe psychiatric , organ transplantation , cancer , seizure disorder pancreatitis disease . 7 . An active suspected malignancy history malignancy within last five year . 8 . Patients documented drug alcohol addiction free history least 12 month , opinion investigator unlikely relapse , may enrol study . 9 . Positive result drug abuse screening.Occasional use cannabis previously randomization exclusion criterion investigator team criterion . The patient advise abstinence trial ( AM 6 ) 10 . Haemoglobin &lt; 12.0g/dL woman , &lt; 13.0g/dL men screen . 11 . White blood cell count &lt; 2000 cells/mm3 screen . 12 . Absolute neutrophil count &lt; 1500 cells/mm3 screen . 13 . Platelet count &lt; 100.000 cells/mm3 screening . 14 . ALT AST level ≥ 5 xULN screening . 15 . Prothrombin time INR prolong 1.5xULN screening . 16 . TSH T4 outside normal limit adequately control thyroid function screening . 17 . Poorly control diabetes mellitus evidence HbA1c &gt; 7.5 % screening . 18 . Alfafetoprotein value &gt; 100ng/mL screening . 19 . Total bilirubin &gt; 1.5xULN ratio direct/indirect &gt; 1 , screen unless predominantly conjugate reflect Gilbert 's disease 20 . Estimated creatinine clearance 30 mL/minute less screen . 21 . Women confirm pregnant 22 . People know hypersensitivity ingredient investigational agent 23 . Patients risk bleed . 24 . Haemoglobinopathy 25 . Screening ECG QTc value ≥ 450ms and/or clinically significant ECG finding . 26 . History clinically significant drug allergy . 27 . Participation clinical study investigational drug , biologic , device within 3 month prior anticipate dose administration . 28 . Any chronic viral ( include HSV ) , bacterial , mycobacterial , fungal , parasitic , protozoal infection . 29 . Requirement chronic systemic corticosteroid . 30 . Receiving systemic antiviral , hematopoietic growth factor , immunomodulatory treatment within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Chronic Hepatitis C Viral Infection</keyword>
	<keyword>Interferon alfa-5</keyword>
	<keyword>Interferon</keyword>
</DOC>